1420800-30-1

Basic information

• Product Name: 1-BroMo-2,4-difluoro-3-nitrobenzene
• Synonyms: 1-BroMo-2,4-difluoro-3-nitrobenzene;3-Bromo-2,6-difluoronitrobenzene 97%;3-Bromo-2,6-difluoronitrobenzene97%;OZKHXLKTMAVPFF-UHFFFAOYSA-N
• CAS NO: 1420800-30-1
• Molecular Formula: C6H2BrF2NO2
• Molecular Weight: 237.9863864
• Mol File: 1420800-30-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-BroMo-2,4-difluoro-3-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BroMo-2,4-difluoro-3-nitrobenzene(1420800-30-1)
• EPA Substance Registry System: 1-BroMo-2,4-difluoro-3-nitrobenzene(1420800-30-1)

Safety Data

• Hazardous Substances Data: 1420800-30-1(Hazardous Substances Data)

Usage

Appearance

Yellow crystalline solid

Uses

a. Synthesis of pharmaceuticals
b. Synthesis of agrochemicals
c. Preparation of dyes and pigments

Reactivity

High due to the presence of bromine, fluorine, and nitro groups

Importance

Acts as an important building block in organic synthesis

Safety precautions

Toxic and harmful if ingested or inhaled, requires careful handling

Upstream product

• 19064-24-5 2,6-difluoro-1-nitrobenzene 

Relevant articles and documents

Discovery of DDO-2213 as a Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia

WD repeat-containing protein 5 (WDR5) is essential for the stability and methyltransferase activity of the mixed lineage leukemia 1 (MLL1) complex. Dysregulation of theMLL1gene is associated with human acute leukemias, and the direct disruption of the WDR5-MLL1 protein-protein interaction (PPI) is emerging as an alternative strategy for MLL-rearranged cancers. Here, we represent a new aniline pyrimidine scaffold for WDR5-MLL1 inhibitors. A comprehensive structure-activity analysis identified a potent inhibitor 63 (DDO-2213), with an IC50of 29 nM in a competitive fluorescence polarization assay and aKdvalue of 72.9 nM for the WDR5 protein. Compound 63 selectively inhibited MLL histone methyltransferase activity and the proliferation of MLL translocation-harboring cells. Furthermore, 63 displayed good pharmacokinetic properties and suppressed the growth of MV4-11 xenograft tumors in mice after oral administration, first verifying thein vivoefficacy of targeting the WDR5-MLL1 PPI by small molecules.

3-BENZOYL-1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS MKK4 INHIBITORS FOR TREATING LIVER DISEASES

The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein

Azacycle diketone compound and preparation method thereof (by machine translation)

The invention provides a azacyclodiketone compound which is characterized by being a compound represented by the following structure. The compound has inhibitory activity on cap-dependent endonuclease. (by machine translation)

Aniline WDR5 protein-protein interaction inhibitor as well as preparation method and application thereof

The invention discloses a WDR5 protein-protein interaction inhibitor. The WDR5 protein-protein interaction inhibitor comprises a compound with a structure shown as a general formula (I). Experiments show that the inhibitor acts on WDR5 protein and interacting proteins thereof including but not limited to MLL, selectively inhibits the proliferation of leukemia cells, inhibits the methylation of H3K4 and the expression of downstream Hox/Meis-1 at the cell level. The invention also discloses a preparation method of the inhibitor as well as an application in preparing drugs for treating acute leukemia and other related diseases. (Shown in the description).

5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE AND 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE DERIVATIVES AS C-MYC AND P300/CBP HISTONE ACETYLTRANSFERASE INHIBITORS FOR TREATING CANCER

The invention is directed to substituted 5-(1H-benzo[d]imidazo-2-yl)- pyridin-2-amine and 5-(3H-imidazo[4,5-b]pyridin-6-yl)-pyridin-2-amine derivatives. Specifically, the invention is directed to compounds according to Formula (lb) wherein R', R2', R3', R4', Rs', R6', R7', and X1' are as defined herein; or a salt thereof including a pharmaceutically acceptable salt thereof. The compounds of the invention decrease MYC protein (c-MYC) in cells and/or inhibit p300/CBP histone acetyltransferase and can be useful in the treatment of cardiac hypertrophy, diabetes, obesity and nonalcoholic fatty liver disease, HIV, polycystic kidney disease, inflammatory diseases, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, multiple sclerosis, cancer and pre-cancerous syndromes, and diseases associated with dysregulation of Myc or inhibition of p300/CBP histone acetyltransferase. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention still further discloses methods of reducing MYC protein (c-MYC) in cells and inhibiting p300/CBP histone acetyltransferase activity, and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS

A series of 2-imino-6-methyltetrahydropyrimidin-4(lH)-one derivatives, substituted in the 6-position by a phenyl moiety which in turn is meta-substituted by an optionally substituted unsaturated fused bicyclic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.

THERAPEUTIC COMPOUNDS AND USES THEREOF

The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.